Previous Page  23 / 24 Next Page
Information
Show Menu
Previous Page 23 / 24 Next Page
Page Background

Not too rare to care

The rarity of MPS counts against early diagnosis

1–3

Collectively affecting only one in 22,500 births,

3

the

very rarity of mucopolysaccharidoses (MPSs), together

with a varied and subtle clinical presentation, make

early diagnosis difficult.

1,2,4

This can expose patients to

irreversible organ damage that treatment may prevent.

1,2,4

To assist in the diagnosis of rare diseases like MPS,

Sanofi Genzyme is providing paediatricians with access

to a highly-sophisticated differential checklist built on a

database of 6,000 diseases.

To register for

FREE* access visit

RDaware

.com.au

*Free access until 14th May 2018.

References: 1. Meikle PJ

et al.

JAMA

1999; 281: 249-54. 2. Muenzer J.

J Pediatr

2004; 144: S27-S34.

3. Muenzer J

et al. Pediatrics

2009; 123 (1): 19-29. 4. Burton BK, Giugliani R.

Eur J Pediatr

2012; 171: 631-9.

sanofi-aventis Australia Pty Ltd trading as Sanofi Genzyme. ABN 31 008 558 807. Talavera Corporate Centre

Building D 12-24 Talavera Road. Macquarie Park, NSW 2113. GZANZ.ALDU.15.01.0025(1). July 2017. MPS0024